CTOs on the Move

Open Biosystems

www.openbiosystems.com

 
Open Biosystems is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Citizens Choice Healthplan

Citizens Choice Healthplan is a Cerritos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImprimisRx

ImprimisRx® is a pharmaceutical company dedicated to delivering high-quality and innovative medicines to physicians and patients at affordable prices. We are pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high-quality formulations that are supported by the clinical experience of physicians and their patients. We offer proprietary compounded ophthalmic formulations. All of our innovative drug formulations are born from the clinical experience of physicians and pharmacist formulators. We are focused on people, and believe our unique business model provides us with the opportunity to address unmet patient needs while delivering high quality and affordable medical solutions to physicians and patients.

Kimberly-Clark

Kimberly-Clark Corporation is an American multinational personal care corporation that produces mostly paper-based consumer products.

Quality Packaging L L C

Quality Packaging L L C is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Burlington, NJ. To find more information about Quality Packaging L L C, please visit www.qpsiusa.com

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.